Dystonia

Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence

Saturday, May 23, 2020 - 6:00am

The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections.

Key Points: 
  • The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections.
  • Symptom recurrence significantly impacted patients quality of life, including sleep, relationships, performance of daily tasks and working lives.
  • Eligible participants were over 18 years old and had (or cared for someone with) spasticity or cervical dystonia (CD) treated with BoNT-A for at least one year.
  • How do patients with cervical dystonia (CD) experience their botulinum neurotoxin type a (BoNT-A) treatment cycle: results from an international online survey.

Deep Brain Stimulation Devices Market To Grow Rapidly Due To Technological Enhancements Such As Integrated Pulse Generators and Robot-Assisted Implantations | Radiant Insights, Inc.

Monday, February 24, 2020 - 10:10am

Deep brain stimulation (DBS) is a device of neurostimulation that comprises the activation of brain neurons using electric stimulation.

Key Points: 
  • Deep brain stimulation (DBS) is a device of neurostimulation that comprises the activation of brain neurons using electric stimulation.
  • Technological enhancements such as integrated pulse generators, customized programming, and robot-assisted implantations will boost product demand in the near future.
  • Based on applications, the deep brain stimulation devices industry is categorized into Dystonia, Parkinson's disease, essential tremor, and others.
  • In this report, global Deep Brain Stimulation Devices Market 2019 by Manufacturers, Regions, Type and Application, forecast to 2025 offers a comprehensive theory of the global Deep Brain Stimulation Devices market.

Deep Brain Stimulation Devices Market to Grow Rapidly Due to Technological Enhancements Such as Integrated Pulse Generators and Robot-Assisted Implantations | Radiant Insights, Inc.

Monday, February 24, 2020 - 10:10am

Deep brain stimulation (DBS) is a device of neurostimulation that comprises the activation of brain neurons using electric stimulation.

Key Points: 
  • Deep brain stimulation (DBS) is a device of neurostimulation that comprises the activation of brain neurons using electric stimulation.
  • Technological enhancements such as integrated pulse generators, customized programming, and robot-assisted implantations will boost product demand in the near future.
  • Based on applications, the deep brain stimulation devices industry is categorized into Dystonia, Parkinson's disease, essential tremor, and others.
  • In this report, global Deep Brain Stimulation Devices Market 2019 by Manufacturers, Regions, Type and Application, forecast to 2025 offers a comprehensive theory of the global Deep Brain Stimulation Devices market.

Medtronic Receives CE Mark Approval for the Percept™ PC Neurostimulator DBS System with BrainSense™ Technology

Thursday, January 9, 2020 - 1:00pm

ThePercept PC neurostimulator is approved in the EU for the treatment of symptoms associated with Parkinsons disease (PD), essential tremor, primary dystonia as well as epilepsy and obsessive-compulsive disorder (OCD).

Key Points: 
  • ThePercept PC neurostimulator is approved in the EU for the treatment of symptoms associated with Parkinsons disease (PD), essential tremor, primary dystonia as well as epilepsy and obsessive-compulsive disorder (OCD).
  • Percept PC with BrainSense technology is a game changer.
  • With this technology, doctors could tailor therapy more precisely to the individual needs of each patient based on data from neuronal activity.
  • Since 1987, more than 150,000 Medtronic DBS devices have been implanted worldwide for movement disorders and other indications.

Aleva Neurotherapeutics Receives CE Mark for its directSTIM™ Deep Brain Stimulation System and Raises USD 8 Million Private Equity

Monday, December 16, 2019 - 8:55am

Lausanne, Switzerland, December 16, 2019 Aleva Neurotherapeutics, a leading developer of implants for deep brain stimulation (DBS) in major neurological indications such as Parkinsons disease and essential tremor, today announced that it has been awarded the CE Mark for its flagship product, the directSTIMTM Deep Brain Stimulation System.

Key Points: 
  • Lausanne, Switzerland, December 16, 2019 Aleva Neurotherapeutics, a leading developer of implants for deep brain stimulation (DBS) in major neurological indications such as Parkinsons disease and essential tremor, today announced that it has been awarded the CE Mark for its flagship product, the directSTIMTM Deep Brain Stimulation System.
  • At present, Aleva is the only emerging technology company to be awarded the CE-Mark for Deep Brain Stimulation.
  • The Company also announced it has raised USD 8 million in a first closing of a Series E financing round from existing and undisclosed new private investors.
  • Deep brain stimulation (DBS) is approved worldwide for the treatment of Parkinsons disease (PD), essential tremor, dystonia, obsessive-compulsive disorder (OCD) and epilepsy.

Imaging in Movement Disorders: Imaging Applications in Non-Parkinsonian and Other Movement Disorders, Vol 143: International Review of Neurobiology - ResearchAndMarkets.com

Tuesday, November 26, 2019 - 12:20pm

The "Imaging in Movement Disorders: Imaging Applications in Non-Parkinsonian and Other Movement Disorders, Vol 143. International Review of Neurobiology" book from Elsevier Science and Technology has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Imaging in Movement Disorders: Imaging Applications in Non-Parkinsonian and Other Movement Disorders, Vol 143. International Review of Neurobiology" book from Elsevier Science and Technology has been added to ResearchAndMarkets.com's offering.
  • Imaging in Movement Disorders: Imaging in Other Movement Disorders and Dementia, Volume 143 provides an up-to-date textbook on the use of imaging modalities across the spectrum of movement disorders and dementias.
  • Specific chapters cover Neuroimaging Applications in Dystonia, Neuroimaging Applications in Essential Tremor, Neuroimaging applications in Restless Leg Syndrome, Neuroimaging Application in Tourette's Syndrome and TIC Disorders, Neuroimaging Applications in Functional Movement Disorders, and Neuroimaging Applications in Cerebellar Disorders.
  • Neuroimaging Applications in Functional Movement Disorders Luis Pedro Faria de Abreu, Tiago Teodoro and Mark J. Edwards
    7.

Michael J. Fox Foundation Honors Antonio Pisani, MD, PhD, and David G. Standaert, MD, PhD, with Bachmann-Strauss Prize for Excellence in Dystonia Research

Monday, November 18, 2019 - 4:20pm

Fox and Todd Sherer, PhD, MJFF CEO, presented the prize to Pisani and Standaert at a Foundation event in New York City on November 16, 2019.

Key Points: 
  • Fox and Todd Sherer, PhD, MJFF CEO, presented the prize to Pisani and Standaert at a Foundation event in New York City on November 16, 2019.
  • Read more about the Bachmann-Strauss Prize for Excellence in Dystonia Research and the contributions of its recipients on the MJFF website.
  • The Bachmann-Strauss Prize for Excellence in Dystonia Research was established in September 2014 with a leadership commitment from the Bachmann-Strauss Dystonia and Parkinson Foundation (BSDPF).
  • This major dystonia research prize broadens public awareness and recognizes key scientific discoveries in dystonia.

Russ T. Shimizu, M.D. is recognized by Continental Who's Who

Wednesday, September 4, 2019 - 5:47pm

is being recognized by Continental Who's Who as a Pinnacle Lifetime Achiever in the field of Medicine as a Neurologist at Neurological Associates of West Los Angeles.

Key Points: 
  • is being recognized by Continental Who's Who as a Pinnacle Lifetime Achiever in the field of Medicine as a Neurologist at Neurological Associates of West Los Angeles.
  • Dedicated to his patients and community for 40 years of service, Dr. Shimizu provides compassionate care for patients who have all types of neurological disorders, including with medication-resistant depression.
  • Specializing in severe depression, arm pain, cervical dystonia, headaches, migraines, and peripheral neuropathy, he's also available to provide second opinions on neurological conditions and neurosurgery.
  • Previously, Dr. Shimizu served as Assistant Clinical Professor of Neurology at UCLA and a Clinical Professor at USC.

Canadian-Developed Treatment Slows Progression of Debilitating Neurodegenerative Disorder

Thursday, June 13, 2019 - 9:14pm

It is most severe when diagnosed in infants, but is equally debilitating in adults, although deterioration is at a slower rate.

Key Points: 
  • It is most severe when diagnosed in infants, but is equally debilitating in adults, although deterioration is at a slower rate.
  • During the study, 21 percent of the placebo group required additional medications for dystonia, while only 11 percent of the treatment group did.
  • "Although the clinical benefit for PKAN patients was quite limited, any slowing of disease progression in this devastating disorder is an important step," Klopstock said.
  • ApoPharma is focused on developing and commercializing products for patients with debilitating and life-threating diseases in which iron plays a role.

FDA Approves Broadened Indication for XEOMIN® (IncobotulinumtoxinA) as First-Line Treatment for Blepharospasm (Involuntary Blinking) in Adult Patients

Monday, May 13, 2019 - 3:15pm

Patients were defined as treatment-nave if at least 12 months had passed since their last toxin treatment.

Key Points: 
  • Patients were defined as treatment-nave if at least 12 months had passed since their last toxin treatment.
  • XEOMIN was first approved by the FDA in 2010 for the treatment of blepharospasm (previously treated with onabotulinumtoxinA) and cervical dystonia in adult patients and later in 2015 for upper limb spasticity in adult patients.
  • Most recently, XEOMIN was approved by the FDA in July 2018 to treat chronic sialorrhea (excessive drooling) in adult patients.
  • Call your healthcare provider or get medical care right away if you have eye pain or irritation after treatment with XEOMIN.